Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer
Status:
Unknown status
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
This study is a phase 1/2a, open label, dose escalation and safety study of APC-100
(2,2,5,7,8-Pentamethyl-6-chromanol) in men with advanced prostate cancer.